Lantheus Holdings Inc (LNTH)
NASDAQ:LNTH
Want to see LNTH full AI Analyst Report?
Top Page
Lantheus
(NASDAQ:LNTH)
Select Model
Select Model
Rating:84Outperform
Price Target:
$109.00
▲(30.04% Upside)
Action:Reiterated
Date:05/09/26
LNTH scores well primarily on strong financial performance (profitability, cash generation, and sharply reduced leverage). Technicals also support the score with a clear uptrend, though overbought signals add near-term risk. Valuation is favorable on a low P/E, while the latest earnings call was constructive on guidance and regulatory progress but tempered by margin/expense pressure and competitive and regulatory uncertainties.
Positive Factors
Balance Sheet Strength
A dramatic deleveraging to near-zero leverage materially increases financial flexibility over the medium term. It supports sustained R&D, bolt-on M&A, share repurchases or buffering pricing cycles without forcing distress sales, improving durability of capital allocation.
Negative Factors
Competitive Pricing Pressure (PYLARIFY)
Reported revenue decline despite rising volume indicates structural pricing erosion in the PSMA PET market. Persistent price competition or reimbursement shifts can compress long‑run revenue and margins for the company’s largest product absent differentiation or pricing power improvements.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A dramatic deleveraging to near-zero leverage materially increases financial flexibility over the medium term. It supports sustained R&D, bolt-on M&A, share repurchases or buffering pricing cycles without forcing distress sales, improving durability of capital allocation.
Read all positive factors
Lantheus (LNTH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$6.26B
Dividend YieldN/A
Average Volume (3M)880.67K
Price to Earnings (P/E)10.4
Beta (1Y)0.62
Revenue Growth0.62%
EPS Growth14.77%
CountryUS
Employees808
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.21
Shares Outstanding65,106,080
10 Day Avg. Volume1,162,881
30 Day Avg. Volume880,673
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)4.12
Price to Sales (P/S)2.91
P/FCF Ratio12.69
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue3.72
Enterprise Value/Gross Profit6.16
Enterprise Value/Ebitda15.56
Forecast
1Y Price Target
$103.25Price Target Upside23.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)5.33
Revenue Forecast (FY)$1.47B
Lantheus Business Overview & Revenue Model
Company Description
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultras...
How the Company Makes Money
Lantheus primarily makes money by selling diagnostic imaging products (radiopharmaceuticals and imaging agents) to healthcare providers, hospitals, and imaging centers, with revenue recognized from product sales and, where applicable, related serv...
Lantheus Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 30, 2026
Earnings Call Sentiment Neutral
The call contained meaningful positives — regulatory progress with PYLARIFY TRUVU approval, solid cash generation, NEUROCEQ and DEFINITY growth, and a reaffirmed full-year outlook — balanced against near-term profitability pressure driven by lower oncology reported revenue, higher operating expenses from recent acquisitions and investments, competitive and pricing risks in PSMA PET, and regulatory timing uncertainty for some therapeutic assets. Management emphasized disciplined capital allocation and readiness to launch TRUVU, and expects growth acceleration in 2027, but near-term headwinds keep the tone measured.Positive Updates
FDA Approval of PYLARIFY TRUVU
FDA approved PYLARIFY TRUVU on March 6, 2026. The new formulation offers larger batch sizes and improved stability at higher radioactive concentrations, enabling broader geographic reach and supply flexibility. Management estimates >70% of current PYLARIFY supply is produced at PMF sites equipped to realize TRUVU advantages.
Negative Updates
Oncology Revenue Decline (PYLARIFY reported revenue)
Oncology revenue (PYLARIFY) was $240.9 million in Q1, down 6.5% year-over-year despite volume growth, reflecting net price pressure and competitive dynamics in the PSMA PET space.
Read all updates
Q1-2026 Updates
Positive
Negative
FDA Approval of PYLARIFY TRUVU
FDA approved PYLARIFY TRUVU on March 6, 2026. The new formulation offers larger batch sizes and improved stability at higher radioactive concentrations, enabling broader geographic reach and supply flexibility. Management estimates >70% of current PYLARIFY supply is produced at PMF sites equipped to realize TRUVU advantages.
Read all positive updates
Company Guidance
Lantheus reiterated full‑year 2026 guidance of $1.40–$1.45 billion in revenue and $5.00–$5.25 in adjusted EPS while citing a strong Q1 start: Q1 revenue $377.3M (+1.2% YoY; +8.6% ex‑$25.2M divested spec revenue), reported net income $118.4M and adjusted net income $95.8M (‑12.5% YoY), GAAP diluted EPS $1.80 and adjusted EPS $1.46 (down ~4.6%), operating profit $129.1M (‑10.5%), gross margin 67.0%, operating expenses 32.8% of revenue, and an effective tax rate of 25.3%; product level Q1 results included PYLARIFY $240.9M (‑6.5% YoY; U.S. volume +5.8% YoY), NEUROCEQ $35.4M (+14.3% vs Q4 2025), DEFINITY $84.6M (+6.8% YoY) and strategic partnerships $16.3M (+52.1%). Cash generation remained strong with operating cash flow $125.1M, capex $3.2M, free cash flow $121.9M, cash & equivalents $498.6M, $200M remaining on the buyback authorization and a $750M undrawn revolver; management said guidance is being maintained out of prudence given competitive dynamics and an upcoming CEO transition, while expecting growth acceleration beginning in 2027.Lantheus Financial Statement Overview
Summary
Income Statement
84
Very Positive
Balance Sheet
92
Very Positive
Cash Flow
86
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.55B | 1.54B | 1.53B | 1.30B | 935.06M | 425.21M |
| Gross Profit | 935.17M | 941.95M | 988.29M | 709.54M | 581.70M | 187.69M |
| EBITDA | 369.99M | 403.64M | 515.27M | 491.00M | 81.83M | -25.00M |
| Net Income | 279.03M | 233.56M | 312.44M | 326.66M | 28.07M | -71.28M |
Balance Sheet | ||||||
| Total Assets | 2.35B | 2.23B | 1.98B | 1.65B | 1.32B | 863.78M |
| Cash, Cash Equivalents and Short-Term Investments | 498.58M | 359.12M | 912.81M | 713.66M | 415.65M | 98.51M |
| Total Debt | 803.00K | 738.00K | 619.44M | 616.95M | 583.51M | 191.31M |
| Total Liabilities | 1.13B | 1.14B | 892.33M | 835.26M | 874.11M | 399.35M |
| Stockholders Equity | 1.21B | 1.09B | 1.09B | 815.89M | 447.15M | 464.44M |
Cash Flow | ||||||
| Free Cash Flow | 371.69M | 354.05M | 493.13M | 258.70M | 263.43M | 41.78M |
| Operating Cash Flow | 407.70M | 390.14M | 544.75M | 305.26M | 281.78M | 53.92M |
| Investing Cash Flow | -537.46M | -627.17M | -226.01M | 5.94M | -276.55M | 3.68M |
| Financing Cash Flow | -309.99M | -316.58M | -118.54M | -13.06M | 311.69M | -39.33M |
Lantheus Technical Analysis
Positive
83.82
Price Trends
83.26
Positive
76.48
Positive
66.41
Positive
Market Momentum
3.74
Negative
69.05
Neutral
58.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LNTH, the sentiment is Positive. The current price of 83.82 is below the 20-day moving average (MA) of 89.47, above the 50-day MA of 83.26, and above the 200-day MA of 66.41, indicating a bullish trend. The MACD of 3.74 indicates Negative momentum. The RSI at 69.05 is Neutral, neither overbought nor oversold. The STOCH value of 58.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LNTH.
Lantheus Risk Analysis
Lantheus disclosed 57 risk factors in its most recent earnings report. Lantheus reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lantheus Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
84 Outperform | $6.26B | 10.37 | 24.33% | ― | 0.62% | 14.77% | |
74 Outperform | $1.87B | 13.63 | 17.32% | ― | 37.03% | ― | |
63 Neutral | $2.83B | -324.88 | -2.73% | ― | 16.29% | -145.12% | |
60 Neutral | $3.90B | 16.36 | -144.72% | ― | 7.62% | ― | |
53 Neutral | $2.10B | ― | 41.38% | ― | -12.78% | 1119.53% | |
52 Neutral | $1.54B | -0.83 | -50.65% | 8.48% | -3.62% | -932.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
LNTH
Lantheus
96.09
20.96
27.90%
PRGO
Perrigo Company
11.16
-14.00
-55.65%
SUPN
Supernus Pharmaceuticals
48.69
16.06
49.22%
ANIP
ANI Pharmaceuticals
82.00
22.92
38.79%
HCM
HUTCHMED
11.91
-1.31
-9.91%
AMRX
Amneal Pharmaceuticals
12.23
4.96
68.23%
Lantheus Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Lantheus Shareholders Approve Governance Changes and Incentive Plan
Positive
May 1, 2026
On April 30, 2026, Lantheus shareholders approved a series of corporate governance and compensation measures at the company’s annual meeting, including an amendment to declassify its board of directors over three years and to allow sharehold...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.